In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move ...
At Asembia AXS26, Clarivate’s Dee Chaudhary outlined how U.S. drug pricing policy is rapidly shifting, driving more ...
As a variety of issues continue to impact the global supply chain, pharmaceutical and biotech companies must plan for ...
FDA approves Breztri Aerosphere for asthma, introducing the first single-inhaler triple-combination maintenance therapy for ...
In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski vice president, strategic market ...
Ireland has evolved into one of the world’s most critical locations for the global Pharmaceutical Industry. Today, with more ...
Sun Pharma will pay $14.00 per share cash for Organon, targeting early-2027 close subject to regulatory and shareholder ...
Dr. Stella Vnook explains how US pricing regulations, such as MFN and the IRA, are forcing pharma companies to adjust ...
The most important issue the industry faces is healthcare and drug pricing. With 2026 being a key election year, regulators ...
What biopharma companies need to know about this evolving regulatory pathway. The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious ...
Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...
FDA label expansion adds relapse-prevention in adult schizophrenia, addressing a major driver of hospitalization, functional deterioration, and caregiver burden in chronic disease management. A Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results